852227-97-5 Usage
Uses
Used in Pharmaceutical Synthesis:
1-[3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine is utilized as a key building block in the synthesis of various pharmaceuticals. Its unique boron-containing heterocycle allows for the formation of carbon-carbon and carbon-heteroatom bonds, facilitating the creation of complex molecular structures with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 1-[3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine serves as an intermediate for the development of new pesticides and herbicides. Its ability to form diverse chemical bonds makes it a valuable component in designing effective and targeted agrochemicals.
Used in Material Science:
1-[3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine is also employed in material science as a precursor for creating advanced materials with specific properties. Its reactivity and structural features contribute to the development of materials with applications in various fields, such as electronics, coatings, and polymers.
Used in Catalysis:
1-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]PIPERIDINE has potential applications in catalysis, where it can act as a catalyst or a catalyst precursor in various organic reactions. Its boron-containing heterocycle may participate in catalytic cycles, enhancing the efficiency and selectivity of chemical transformations.
Overall, 1-[3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine is a versatile chemical entity with broad applications across different industries, including pharmaceuticals, agrochemicals, materials science, and catalysis, owing to its unique structure and reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 852227-97-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,2,2,2 and 7 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 852227-97:
(8*8)+(7*5)+(6*2)+(5*2)+(4*2)+(3*7)+(2*9)+(1*7)=175
175 % 10 = 5
So 852227-97-5 is a valid CAS Registry Number.
InChI:InChI=1/C17H26BNO2/c1-16(2)17(3,4)21-18(20-16)14-9-8-10-15(13-14)19-11-6-5-7-12-19/h8-10,13H,5-7,11-12H2,1-4H3
852227-97-5Relevant academic research and scientific papers
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00567; 00569; 001058; 001059, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00609; 00610; 00612; 001100; 001101; 001102, (2019/07/17)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis
Patel, Gautam,Karver, Caitlin E.,Behera, Ranjan,Guyett, Paul J.,Sullenberger, Catherine,Edwards, Peter,Roncal, Norma E.,Mensa-Wilmot, Kojo,Pollastri, Michael P.
supporting information, p. 3820 - 3832 (2013/06/27)
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b
